SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/12/20 Phibro Animal Health Corp 8-K:5 2/07/20 1:18K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 12K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
__________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 12, 2020 (February 7, 2020)
Phibro Animal Health Corporation
___________________________
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
Delaware | 01-36410 | 13-1840497 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Glenpointe Centre East, 3rd Floor
300 Frank W. Burr Boulevard, Suite 21
Teaneck, New Jersey 07666-6712
_______________________________________
(Address of Principal Executive Offices, including Zip Code)
(201) 329-7300
__________________________________
(Registrant’s telephone number, including area code)
Not Applicable
__________________________________
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Class A Common Stock, $0.0001 par value per share | PAHC | NASDAQ Stock Market |
Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAN OFFICERS.
(b) On February 7, 2020, Dr. George Gunn, a member of the Board of Directors (the “Board”) of Phibro Animal Health Corporation (the “Company”), informed the Company that he intended to resign his position as Director of the Company effective immediately to devote more time to other personal and business interests. Dr. Gunn was a Class III director of the Company and also served on the Company’s Compensation Committee. Dr. Gunn’s resignation was not the result of any disagreement with the Company. The Board has not filled the vacancy left by Dr. Gunn’s resignation.
In connection with Dr. Gunn’s resignation, Jack C. Bendheim, the Company’s Chairman of the Board, President, and Chief Executive Officer stated, “The Company sincerely thanks Dr. Gunn for his valuable contributions to the Company as a member of our Board for nearly five years, and we wish him continued success in his future endeavors.”
C:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
PHIBRO ANIMAL HEALTH CORPORATION Registrant | ||
Date: February 12, 2020 | ||
By: | /s/ Thomas G. Dagger | |
Name: Title: |
Thomas G. Dagger Senior Vice President, General Counsel and Corporate Secretary |
C:
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 2/12/20 | SC 13G/A | ||
For Period end: | 2/7/20 | |||
List all Filings |